The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: A quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis

American Journal of Physiology - Endocrinology and Metabolism

Volumn 303, Issue 2, 2012, Pages

  Vrang, Niels ^a   Jelsing, Jacob ^a   Simonsen, Lotte ^b   Jensen, Andres Eskjaer ^a   Thorup, Inger ^b   Søeborg, Henrik ^b   Knudsen, Lotte Bjerre ^b  

^a Gubra ApS   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

cell mass; Exenatide; Glucagon like peptide 1 receptor agonists; Stereology

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; LIRAGLUTIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; MALE; NONHUMAN; ORGAN WEIGHT; OSMOTIC MINIPUMP; PANCREAS FUNCTION; PANCREAS ISLET BETA CELL; PANCREATITIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; SEX DIFFERENCE; STEREOLOGY; TREATMENT DURATION; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; LIPASE; MALE; PANCREAS; PANCREATIC ALPHA-AMYLASES; PANCREATITIS; PEPTIDES; RATS; RATS, ZUCKER; VENOMS;

EID: 84863950236     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00182.2012     Document Type: Article

References (45)

1. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 358: 1970-1971; discussion 1971-1972, 2008.
2. Ayoub WA, Kumar AA, Naguib HS, Taylor HC. Exenatide-induced acute pancreatitis. Endocr Pract 16: 80-83, 2010.
3. Bouwens L, Braet F, Heimberg H. Identification of rat pancreatic duct cells by their expression of cytokeratins 7, 19, and 20 in vivo and after isolation and culture. J Histochem Cytochem 43: 245-253, 1995.
4. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374: 39-47, 2009.
5. Butler AE, Galasso R, Matveyenko A, Rizza RA, Dry S, Butler PC. Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 53: 21-26, 2010.
6. Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R. Glucagonlike peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 53: 1-6, 2010.
7. Collombat P, Mansouri A. Turning on the beta-cell identity in the pancreas. Cell Cycle 8: 3450-3451, 2009.
8. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 29: 471, 2006.
9. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13: 559-566, 2011.
10. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25: 1019-1027, 2009.
11. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.
12. Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies-review of the scientific evidence. J Clin Endocrinol Metab 96: 2027-2031, 2011.
13. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141: 150-156, 2011.
14. Elayat AA, el-Naggar MM, Tahir M. An immunocytochemical and morphometric study of the rat pancreatic islets. J Anat 186: 629-637, 1995.
15. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405, 1992.
16. Fredriksson A, Jacobson G. Influence of renal function on the urinary excretion of amylase. An experimental study in the rat. Scand J Clin Lab Invest 33: 313-321, 1974.
17. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet 371: 143-152, 2008.
18. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 33: 2349-2354, 2010.
19. Gedulin BR, Nikoulina SE, Smith PA, Gedulin G, Nielsen LL, Baron AD, Parkes DG, Young AA. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146: 2069-2076, 2005.
20. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the KrasG12D Mouse Model. Diabetes 61: 1250-1262, 2012.
21. Gundersen HJ, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263, 1987.
22. Junge W, Malyusz M, Ehrens HJ. The role of the kidney in the elimination of pancreatic lipase and amylase from blood. J Clin Chem Clin Biochem 23: 387-392, 1985.
23. Kloppel G, Maillet B. Pathology of acute and chronic pancreatitis. Pancreas 8: 659-670, 1993.
24. Koehler JA, Baggio LL, Lamont BJ, Ali S, Drucker DJ. Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58: 2148-2161, 2009.
25. Liu Z, Habener JF. Alpha cells beget beta cells. Cell 138: 424-426, 2009.
26. Malhotra R, Singh L, Eng J, Raufman JP. Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini. Regul Pept 41: 149-156, 1992.
27. Malyusz M, Wrigge P, Caliebe D, Junge W. Renal handling of 125Ilabelled homologous pancreatic lipase and amylase in the rat. J Clin Chem Clin Biochem 26: 611-615, 1988.
28. Matveyenko AV, Dry S, Cox HI, Moshtaghian A, Gurlo T, Galasso R, Butler AE, Butler PC. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58: 1604-1615, 2009.
29. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, Taylor R, Quinn T, Weide L, Alba LM. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53: 153-159, 2010.
30. Nyborg NC, Mølck AM, Madsen LW, Bjerre Knudsen L. The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species. Diabetes 61: 1243-1249, 2012.
31. Paulsen SJ, Vrang N, Larsen LK, Larsen PJ, Jelsing J. Stereological assessment of pancreatic beta-cell mass development in male Zucker Diabetic Fatty (ZDF) rats: correlation with pancreatic beta-cell function. J Anat 217: 624-630, 2010.
32. Raufman JP, Singh L, Singh G, Eng J. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. J Biol Chem 267: 21432-21437, 1992.
33. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, Knudsen LB. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases β-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 283: E745-E752, 2002.
34. Singh G, Eng J, Raufman JP. Use of 125I-[Y39]exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig. Regul Pept 53: 47-59, 1994.
35. Strobel O, Rosow DE, Rakhlin EY, Lauwers GY, Trainor AG, Alsina J, Fernández-Del Castillo C, Warshaw AL, Thayer SP. Pancreatic duct glands are distinct ductal compartments that react to chronic injury and mediate Shh-induced metaplasia. Gastroenterology 138: 1166-1177, 2010.
36. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, Wilken M, Wassermann K, Deacon CF, Carr RD, Knudsen LB. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 140: 123-132, 2003.
37. Tang-Christensen M, Larsen PJ, Göke R, Fink-Jensen A, Jessop DS, Møller M, Sheikh SP. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integr Comp Physiol 271: R848-R856, 1996.
38. Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 299: E1076-E1086, 2010.
39. Teague J, Gyte A, Peel JE, Young KC, Loxham SJ, Mayers RM, Poucher SM. Reversibility of hyperglycaemia and islet abnormalities in the high fat-fed female ZDF rat model of type 2 diabetes. J Pharmacol Toxicol Methods 63: 15-23, 2011.
40. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India 56: 987-988, 2008.
41. US Food and Drug Administration. Byetta (exanatide) Injection NDA 21-773: Drug Approval Package (04-28-2005) (Online). http://www.accessdata. fda.gov/drugsatfda_docs/nda/2005/021773_ByettaTOC.cfm [25 May 2012].
42. US Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers-Liraglutide (Marketed as Victoza) Information: US Department of Health and Human Services, 2010 (Online). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm198437.htm [25 May 2012].
43. US Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers-Sitagliptin (Markteted as Januvia and Janumet) Information (09-25-2009): US Department of Health and Human Services, 2009 (Online). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm183768.htm [25 May 2012].
44. Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, Bonner-Weir S. GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts. Diabetes Res Clin Pract 73: 107-110, 2006.
45. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48: 2270-2276, 1999.